No CYP-affinity. However, side effects such as nausea and vomiting may be potentially porphyrinogenic through reduction in carbohydrate intake.

Catumaxomab is a rodent hybrid monoclonal antibody.

Catumaxomab is indicated for malignant ascites, secondary to epithelial cell adhesion molecule positive carcinoma where standard treatment is not available or not any longer possible. Common side effects that can be confused with an acute porphyria attack are nausea, vomiting, abdominal pain, diarrhoea, obstipation and dorsal pain. Other common side effects are infections and anorexia. A common side effect is cytokine release syndrome. Cytokines such as IL-1, IL-6 and TNF liberated in response to inflammation, infection of tissue destruction, modulate the expression of PXR, CAR, HNF-4 and NF-kB in a way to damp the hepatic expression of drug metabolizing CYP-genes (Breslin 2007, Christensen 2012). They also activate nitric oxide synhase-2 (NOS-2) which inhibit drug metabolizing CYPs directly via destabilization of the protein structure (Lee 2010).

Insignificant and irrelevant

Catumaxomab is not metabolized by CYP-enzymes, but are degraded to peptides and amino acids that can be re-used in the body for de novo synthesis of proteins or are excreted by the kidney (Keizer 2010).